Golden Developing Solutions Inc (OTCMKTS: DVLP) is an exciting story in small caps that is under accumulation since reversing off $0.002 lows. Since its days in the CBD business ended, DVLP has recently acquired 4 specialty pharmacy acquisitions that have transformed the Company into a significant revenue’s producer. In February the Company reported it has achieved unaudited December 2022 sales of $5,658,865.07 with the largest customer still to be onboarded. With this addition the Company is at its targeted run rate from the acquisitions. 

DVLP is an SEC filer, and we are currently waiting on the 10k that will show the revenues from the acquisitions as the 10Q from November did not include any data from the 4 pharmacy acquisitions. Led by ambitious CEO Stavros Triant, DVLP is in the process of reviewing other acquisitions in the specialty pharmacy industry. DVLP also recently removed 320 million shares from circulation through the conversion of shares of common stock controlled by the Company’s CEO, Stavros Triant. We will be updating on DVLP when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Golden Developing Solutions Inc (OTCMKTS: DVLP) is a public online health and wellness start-up company. Its pharmaceutical division specializes in providing specialty medicine with rapid delivery services and adequate medical support in the United State. The recent 4 specialty pharmacy acquisitions in 2022 have capacitated the company’s service offerings to the State of Michigan and Florida with a projected consolidated revenue of $100M. DVLP aims to position itself to build shareholder value by setting the highest standards in service, reliability, and safety in our rapidly growing industry. 

DVLP has an aggressive and promising strategy in the specialty pharmacy space and is in the process of reviewing other acquisitions in the specialty pharmacy industry. Management to date has completed the acquisitions of Orchard Trails Pharmacy in Farmington, MI; New Hudson Pharmacy in New Hudson, MI; Bushnell Pharmacy In Bushnell, FL and Sai Siva Healthcare in Miami, FL. Between 2015 and 2021, specialty pharmacies grew by 315%, according to data presented at Asembia’s 2022 Specialty Pharmacy Summit,1 with hospital or health system-owned specialty pharmacies accounting for one-third of the total growth. 

In January the Company pledged to remove 320 million shares from circulation through the conversion of shares of common stock controlled by the Company’s CEO, Stavros Triant, into 320,000 shares of Preferred stock, has been approved and completed. DVLP has now completed this process and the total number of common shares trading actively in the market has now been sharply reduced. 

$DVLP $OTC $NASDAQ– This is the real deal! Not many legit OTC companies out there. This is SEC audited doing it the right way also extremely undervalued based on 100 mil revs at 1.4 BIL OS. Just a matter of time before this finds it's true value imo. 🔥 🔥 🔥 https://t.co/SYIwv9XDNx

— Craig G (@cwg8008) March 27, 2023

To Find out the inside Scoop on DVLP Subscribe to newsytrends.com Right Now by entering your Email in the box below

On February 7 DVLP released an update to shareholders and the market, discussing anticipated revenue matters and the state of previously announced acquisitions. The Company has achieved unaudited December 2022 sales of $5,658,865.07 with the largest customer still to be onboarded. With this addition the Company is at its targeted run rate from the acquisitions. 

It also expects a significant increase in revenues after the 4 previously announced acquisitions are fully transitioned. During this final processes of transitioning and onboarding customers we expect a brief dip in Q1 sales followed by a robust rebound and acceleration. After completion, the Company will again begin to acquire more acquisitions in the Specialty Pharmacy market, which also will become another event that should further increase Company revenues, helping it reach its 2023 goals. 

Stavros Triant, CEO of DVLP, said: “First of all, we are happy to see December sales exceeded $5.6 million… along with the final customer onboarding would have easily hit our 2022 monthly run rate. We will finish the transitions in Q1 and begin to grow organically, as well as continue our acquisition strategy. We are holding off closing several targeted additional acquisitions until we complete the state, federal, vendor and other rules, regulations and transitions of the 4 we have already acquired. One of the hurdles was that audit work on acquisitions was behind schedule due to proprietary software reporting systems of third parties. We have concluded what we will need to finish these and take appropriate measures if further time is needed to complete. We will focus on clearing all the hurdles that accompany these types of acquisitions. Because such deals are complicated and that we are doing 4 of these at the same time, its taken a little longer than expected… but we feel that we are on track to garner every single approval required in the very near future. We are very excited about the business model, the industry, and our future plans. The demand for product and the ability to scale are very promising.” 

$dvlp the trend is ur friend. We dip then rip around here pic.twitter.com/pKi0htRhwF

— Cade (@_CCS_) March 23, 2023

 We have something big coming Subscribe Right Now!

Currently trading at a $4.3 million market valuation DVLP os is 1,398,490,663 shares as of March 24, 2023. The Company has a decent balance sheet with well under $1 million in liabilities and is an SEC filer and fully reporting. As we said DVLP is an exciting story in small caps that is under accumulation since reversing off $0.002 lows. DVLP is an SEC filer, and we are currently waiting on the 10k that will show the revenues from the acquisitions as the 10Q from November did not include any data from the 4 pharmacy acquisitions. Led by ambitious CEO Stavros Triant, DVLP is in the process of reviewing other acquisitions in the specialty pharmacy industry. DVLP also recently removed 320 million shares from circulation through the conversion of shares of common stock controlled by the Company’s CEO, Stavros Triant. We will be updating on DVLP when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Disclosure: we hold no position in DVLP either long or short and we have not been compensated for this article.